Payment overview · 2025
General Payments
$1,001.74
46 reported records · 19 companies
Healthcare provider profile · identity verified
Krishna Pandey, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MILWAUKEE, WI · NPI 1669452223
Verified facts
What the public records show
CMS Open Payments records show Krishna Pandey, M.D. received $1,001.74 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Entresto, Ingrezza, Linzess, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 885 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 885 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $247.40 | 24.7% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.30 | 6.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.77 | 6.7% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $66.67 | 6.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.16 | 6.3% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.08 | 5.9% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $54.82 | 5.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.52 | 5.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.18 | 5.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.82 | 4.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $36.39 | 3.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.81 | 3.4% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $29.48 | 2.9% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $28.98 | 2.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.51 | 2.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.91 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.31 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.57 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.06 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,001.74 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $116.95 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $101.19 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.66 | 3 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $66.67 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $59.08 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $54.82 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $52.73 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $50.52 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.26 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $40.85 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.99 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.99 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.99 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 885 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 31 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 143 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
143 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
885 | 131 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
233 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
130 | 23 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
885 | 131 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1647 | 284 |
| Gabapentin | Gabapentin | 1259 | 227 |
| Furosemide | Furosemide | 1225 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 1167 | 205 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1096 | 228 |
| Eliquis | Apixaban | 885 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 861 | 138 |
| Metoprolol Succinate | Metoprolol Succinate | 662 | 143 |
| Tamsulosin Hcl | Tamsulosin Hcl | 623 | 109 |
| Mirtazapine | Mirtazapine | 576 | 103 |
| Lisinopril | Lisinopril | 550 | 104 |
| Metoprolol Tartrate | Metoprolol Tartrate | 547 | 94 |
| Carvedilol | Carvedilol | 477 | 88 |
| Sertraline Hcl | Sertraline Hcl | 475 | 75 |
| Losartan Potassium | Losartan Potassium | 440 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 407 | 68 |
| Allopurinol | Allopurinol | 406 | 69 |
| Levetiracetam | Levetiracetam | 405 | 52 |
| Potassium Chloride | Potassium Chloride | 401 | 87 |
| Omeprazole | Omeprazole | 361 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 358 | 101 |
| Trazodone Hcl | Trazodone Hcl | 342 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 318 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 305 | 76 |
| Metformin Hcl | Metformin Hcl | 289 | 59 |
| Baclofen | Baclofen | 279 | 44 |
| Buspirone Hcl | Buspirone Hcl | 274 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 273 | 66 |
| Midodrine Hcl | Midodrine Hcl | 268 | 64 |
| Quetiapine Fumarate | Quetiapine Fumarate | 264 | 54 |
| Jardiance | Empagliflozin | 233 | 34 |
| Divalproex Sodium | Divalproex Sodium | 210 | 31 |
| Spironolactone | Spironolactone | 205 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 204 | 79 |
| Warfarin Sodium | Warfarin Sodium | 204 | 19 |
| Simvastatin | Simvastatin | 198 | 31 |
| Xarelto | Rivaroxaban | 186 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 183 | 32 |
| Prednisone | Prednisone | 182 | 87 |
| Tradjenta | Linagliptin | 181 | 16 |
| Latanoprost | Latanoprost | 179 | 34 |
| Famotidine | Famotidine | 162 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 160 | 21 |
| Memantine Hcl | Memantine Hcl | 160 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 154 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 150 | 33 |
| Olanzapine | Olanzapine | 147 | 25 |
| Tramadol Hcl | Tramadol Hcl | 145 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 30 |
| Linzess | Linaclotide | 143 | 37 |
| Myrbetriq | Mirabegron | 142 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 27 |
| Alcohol Pads | Alcohol Antiseptic Pads | 134 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 131 | 38 |
| Trulicity | Dulaglutide | 130 | 23 |
| Celecoxib | Celecoxib | 129 | 36 |
| Ozempic | Semaglutide | 128 | 29 |
| Finasteride | Finasteride | 124 | 25 |
| Sevelamer Carbonate | Sevelamer Carbonate | 121 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 25 |
| Bumetanide | Bumetanide | 113 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 108 | 24 |
| Aripiprazole | Aripiprazole | 105 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 104 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 99 | 17 |
| Donepezil Hcl | Donepezil Hcl | 98 | 23 |
| Montelukast Sodium | Montelukast Sodium | 97 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 14 |
| Januvia | Sitagliptin Phosphate | 92 | 16 |
| Bupropion Xl | Bupropion Hcl | 90 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 18 |
| Lokelma | Sodium Zirconium Cyclosilicate | 83 | 13 |
| Topiramate | Topiramate | 83 | 13 |
| Lidocaine | Lidocaine | 82 | 20 |
| Pregabalin | Pregabalin | 81 | 32 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 80 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 79 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 25 |
| Risperidone | Risperidone | 76 | suppressed |
| Lamotrigine | Lamotrigine | 75 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 17 |
| Hydrocortisone | Hydrocortisone | 73 | 19 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 73 | 31 |
| Glipizide | Glipizide | 71 | 15 |
| Clonidine Hcl | Clonidine Hcl | 69 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 13 |
| Alendronate Sodium | Alendronate Sodium | 63 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | suppressed |
| Glimepiride | Glimepiride | 60 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 60 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 58 | suppressed |
| Nystatin | Nystatin | 58 | 32 |
| Sucralfate | Sucralfate | 58 | 14 |
| Ezetimibe | Ezetimibe | 57 | 11 |
| Zenpep | Lipase/Protease/Amylase | 56 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 13 |
| Ketoconazole | Ketoconazole | 54 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 20 |
| Loperamide | Loperamide Hcl | 53 | 17 |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 52 | 19 |
| Lactulose | Lactulose | 51 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 49 | suppressed |
| Nifedipine Er | Nifedipine | 49 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 49 | 19 |
| Acamprosate Calcium | Acamprosate Calcium | 47 | suppressed |
| Clonidine | Clonidine | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 18 |
| Meloxicam | Meloxicam | 47 | 14 |
| Cephalexin | Cephalexin | 46 | 36 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | suppressed |
| Zonisamide | Zonisamide | 45 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Metolazone | Metolazone | 44 | 14 |
| Oxcarbazepine | Oxcarbazepine | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 42 | suppressed |
| Calcium Acetate | Calcium Acetate | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Digoxin | Digoxin | 41 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 18 |
| Levemir | Insulin Detemir | 41 | suppressed |
| Lovastatin | Lovastatin | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 41 | suppressed |
| Torsemide | Torsemide | 40 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 39 | 17 |
| Calcitriol | Calcitriol | 38 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 24 |
| Meclizine Hcl | Meclizine Hcl | 38 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 35 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 34 | 11 |
| Lithium Carbonate | Lithium Carbonate | 34 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 34 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 34 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 32 | 15 |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 13 |
| Tolterodine Tartrate | Tolterodine Tartrate | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 24 |
| Travoprost | Travoprost | 31 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 30 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Glucagon Emergency Kit | Glucagon | 29 | 24 |
| Insulin Lispro | Insulin Lispro | 29 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Restasis | Cyclosporine | 29 | suppressed |
| Admelog Solostar | Insulin Lispro | 28 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | 14 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Nyamyc | Nystatin | 28 | 19 |
| Primidone | Primidone | 28 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Folic Acid | Folic Acid | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Cefdinir | Cefdinir | 26 | 23 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 25 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Cyclosporine | Cyclosporine | 24 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Clotrimazole | Clotrimazole | 23 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | suppressed |
| Minoxidil | Minoxidil | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Repaglinide | Repaglinide | 22 | suppressed |
| Azathioprine | Azathioprine | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 17 |
| Colchicine | Colchicine | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Salsalate | Salsalate | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Diclofenac Potassium | Diclofenac Potassium | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Levocarnitine | Levocarnitine | 20 | suppressed |
| Mirabegron Er | Mirabegron | 20 | 11 |
| Naproxen | Naproxen | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Nystop | Nystatin | 19 | 15 |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ramelteon | Ramelteon | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Acetic Acid | Acetic Acid | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Clozapine | Clozapine | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Teriflunomide | Teriflunomide | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Atovaquone | Atovaquone | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Lamivudine | Lamivudine | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,001.74 · 46 records | ABBVIE INC. | ABRYSVO, Briviact, CAMZYOS, CAPLYTA, COMIRNATY, CREON, ELIQUIS, ENTRESTO, FANAPT, GIMOTI, INGREZZA, Kerendia, LINZESS, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, SUBLOCADE, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOWST, VRAYLAR, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error